Published in J Geriatr Cardiol on February 01, 2017
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 14.95
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 11.81
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Natriuretic peptides. N Engl J Med (1998) 6.04
Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature (1995) 5.91
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA (2009) 5.32
Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J (2010) 5.04
Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation (2003) 4.36
Galectin-3: an open-ended story. Biochim Biophys Acta (2006) 4.10
Soluble CD40 ligand in acute coronary syndromes. N Engl J Med (2003) 4.06
Absolute and attributable risks of cardiovascular disease incidence in relation to optimal and borderline risk factors: comparison of African American with white subjects--Atherosclerosis Risk in Communities Study. Arch Intern Med (2007) 4.05
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med (2000) 3.90
Association between myeloperoxidase levels and risk of coronary artery disease. JAMA (2001) 3.74
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62
Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol (2010) 3.50
The support of human genetic evidence for approved drug indications. Nat Genet (2015) 3.03
High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation (2012) 2.94
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol (2005) 2.77
Release kinetics of inflammatory biomarkers in a clinical model of acute myocardial infarction. Circ Res (2014) 2.70
Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol (2012) 2.59
Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med (2001) 2.52
Preparing the United States for high-sensitivity cardiac troponin assays. J Am Coll Cardiol (2013) 2.46
Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. Br J Obstet Gynaecol (1996) 2.40
Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta (2005) 2.40
Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation (2003) 2.31
Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol (2006) 2.29
Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. J Am Coll Cardiol (2013) 2.28
Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26
Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes (2013) 2.25
Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.22
Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum (2008) 2.19
Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem (2005) 2.10
C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation (2003) 2.09
Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol (2005) 2.07
Uric acid measurement improves prediction of cardiovascular mortality in later life. J Am Geriatr Soc (2013) 2.04
GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med (2011) 2.01
Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J (2007) 1.99
Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J Exp Med (2007) 1.96
High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail (2010) 1.96
Phospholipase A2 biochemistry. Cardiovasc Drugs Ther (2008) 1.93
Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail (2011) 1.92
Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol (2013) 1.78
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA (2014) 1.72
Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation (2004) 1.70
Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol (2013) 1.69
High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol (2004) 1.69
Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol (2007) 1.66
Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet. Arterioscler Thromb Vasc Biol (2006) 1.60
Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J (2012) 1.55
Soluble CD40L and cardiovascular risk in women. Circulation (2001) 1.52
Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis (1995) 1.52
Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem (2004) 1.52
Platelet-activating factor acetylhydrolases. J Biol Chem (1997) 1.51
Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med (2014) 1.49
Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett (2008) 1.48
Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation (2007) 1.45
Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation (2007) 1.41
Comparison of Inflammatory Biomarkers in Outpatients With Prior Myocardial Infarction. Int Heart J (2016) 1.38
Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol (2007) 1.34
Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol (2007) 1.32
Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell (2010) 1.29
Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J (2008) 1.26
Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation (2011) 1.25
Adrenomedullin: potential in physiology and pathophysiology. Life Sci (2000) 1.22
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation (2012) 1.21
Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension (2001) 1.19
Diagnostic accuracy of heart-type fatty acid-binding protein for the early diagnosis of acute myocardial infarction. Am J Emerg Med (2011) 1.15
Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol (2011) 1.12
Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med (2004) 1.12
Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem (2004) 1.08
Uric Acid and Cardiovascular Events: A Mendelian Randomization Study. J Am Soc Nephrol (2015) 1.08
Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem (2011) 1.07
Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men. Eur J Cardiovasc Prev Rehabil (2004) 1.07
Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community. Arterioscler Thromb Vasc Biol (2013) 1.05
Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis (2013) 1.03
ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res (2013) 1.02
Pregnancy-associated plasma protein-a is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events. J Am Coll Cardiol (2006) 1.02
Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. Eur Heart J (2011) 1.02
Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol (1999) 1.01
Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation (2011) 1.01
Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem (2012) 0.99
Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clin Chem (2012) 0.99
Endothelin. Pharmacol Rev (2016) 0.95
34th Bethesda Conference: Task force #3--What is the spectrum of current and emerging techniques for the noninvasive measurement of atherosclerosis? J Am Coll Cardiol (2003) 0.94
Natriuretic peptide family: new aspects. Curr Med Chem Cardiovasc Hematol Agents (2005) 0.93
Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol (2012) 0.93
Protective effect of heme oxygenase-1 on Wistar rats with heart failure through the inhibition of inflammation and amelioration of intestinal microcirculation. J Geriatr Cardiol (2015) 0.76
The future of remote ECG monitoring systems. J Geriatr Cardiol (2016) 0.75